Clinical Efficacy and Bleeding Risk of Tigrilol Combined with Bivaludine in Patients with Acute Coronary Syndrome (ACS) Treated with Emergency PCI
YOU San-li, WANG Zhao
The Second People's Hospital of Hunan Province/Brain Hospital Affiliated to Hunan University of Traditional Chinese Medicine, Changsha, Hunan Province, China,410078
Abstract：【Objective】To investigate the clinical efficacy and bleeding risk of tigrilol combined with bivaludine in patients with acute coronary syndrome (ACS) treated with emergency percutaneous coronary intervention (PCI).【Methods】The clinical data of 116 patients with ACS treated with emergency PCI from November 2016 to November 2017 in Hunan Brain Hospital were retrospectively analyzed and divided into observation group (n=52, administrated with tigrilol before operation and intraoperatively combined with bivaldine) and control group (n=64, administrated with tigrilol before operation intraoperatively combined with common heparin) according to their drug use. Both groups were given aspirin orally before operation. The blood flow grade of thrombolytic test in myocardial infarction was observed during operation, and the clinical effect was observed after operation. Left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVDED) were compared at 7 days after operation. The major cardiovascular events (MACEE) and the incidence of hemorrhage were recorded and compared between the two groups.【Results】There was no significant difference in the number of stents implanted by PCI, and the level of LVEDV and LVEF in both groups at 7 days and 1 month after operation (mean P>0.05), and there was no significant difference between the two groups in the proportion of TIMI blood flow grading and sucking thrombus before and after operation (P>0.05). There was no significant difference in the incidence of MACE, acquired thrombocytopenia and stent thrombosis between the two groups 1 month after operation (mean P>0.05), the total incidence of hemorrhage in the observation group after PCI was lower than that in the control group, and the two groups had slight hemorrhage. The difference was statistically significant (P<0.05).【Conclusion】Tigrilol combined with bivaludine for emergency PCI treatment in ACS patients dose not increase thrombotic events within 30 days and could effectively reduce the incidence of bleeding.
游三丽,王照. 替格瑞洛联合比伐卢定对行急诊PCI术的急性冠脉综合征患者疗效观察[J]. 医学临床研究, 2018, 35(4): 706-709.
YOU San-li, WANG Zhao. Clinical Efficacy and Bleeding Risk of Tigrilol Combined with Bivaludine in Patients with Acute Coronary Syndrome (ACS) Treated with Emergency PCI. JOURNAL OF CLINICAL RESEARCH, 2018, 35(4): 706-709.
[1] Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and interventions[J].Circulation,2011,124(23):e607-609. [2] 王建斌,杨丽,王立新,等.比伐卢定在冠状动脉介入治疗中的临床研究进展[J].中国循环杂志,2013,28(2):156-157. [3] Stone GW,Witzenbichler B,Guagliumi G,et al.Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI):final 3-year results from a multicentre,randomised controlled trial[J].Lancet,2011,377(9784):2193-2204. [4] Bertrand OF,Jolly SS,Rao SV,et al.Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention[J].Am J Cardiol,2012,110(4):599-606. [5] Rassen JA,Mittleman MA,Glynn RJ,et al.Editor's Choice:Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention[J].Eur Heart J,2010,31(5):561-563. [6] Steg PG,James S,Harrington RA,et al.Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis[J].Circulation,2010,122(21):2131-2141. [7] 游三丽,王照.替格瑞洛和氯吡格雷对早期行PCI术的NSTE-ACS合并T2DM患者围术期炎症因子的影[J].医学临床研究,2017,34(5):853-856. [8] Steg P G,Hof A,Hamm CW,et al.Bivalirudin started during emergency transport for primary PCI[J].N Engl J Med,2013,369(23):2207-2208. [9] Han Y,Guo J,Zheng Y,et al.Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction:The BRIGHT Randomized Clinical Trial[J].JAMA,2015,313(13):1336-1337. [10] Leonardi S,Frigoli E,Rothenbühler M,et al.Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX):randomised controlled trial[J].Br Med J,2016 Sep 27;354:i4935. [11] Mahmoud A,Saad M,Elgendy A Y,et al.Bivalirudin in percutaneous coronary intervention,is it the anticoagulant of choice[J]?Cardiovasc Ther,2015,33(4):227-235. [12] Shahzad A,Kemp I,Mars C,et al.Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI):an open-label,single centre,randomised controlled trial[J].Lancet,2014,384(9957):1849-1858. [13] Kern MJ."Conversations in cardiology":How do you pick the best antiplatelet drug--clopidogrel,prasugrel,ticagrelor for your PCI patient[J]?Catheter Cardiovasc Interv,2012,79(2):255-262.
2018, Vol. 35 
